cyrilzakka/clinical-trials huggingface dataset:
AcQMap® Global Registry of Procedural and Long-term Clinical Outcomes (AcQMap Registry)

AcQMap Registry is an observational study

AcQMap Registry is an observational, prospective, multi-center, multi-national, open-label registry designed to provide clinical data regarding the commercial, real-life experience with the diagnostic AcQMap System.

Eligibility Criteria:
Inclusion Criteria:

* Male or female 18 years of age or older.
* Currently scheduled for an ablation of an arrhythmia utilizing the diagnostic AcQMap System.
* Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study.
* Willing and able to give written informed consent.

Exclusion Criteria:

* In the opinion of the Investigator, any known contraindications to an ablation procedure.
* Current enrollment in any study protocol sponsored by Acutus Medical.
* Any other condition that, in the judgment of the investigator, makes the participant a poor candidate for this procedure, the study, or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, extensive travel away from the research center, etc.).
Exercise for Physical Health in Men With Prostate Cancer

The purpose of this study is to conduct a 12-month randomized controlled trial comparing the effects of strength and impact exercise training to flexibility/relaxation training on body composition (bone, muscle and fat mass), physical function (strength, gait, power, balance and self-report physical function and symptoms) in men currently treated with hormone therapy for prostate cancer.

Prostate cancer survivors with advanced disease are commonly treated with androgen deprivation therapy (ADT) to reduce testosterone. Serious side effects of ADT are rapid bone and muscle loss that can lead to osteoporosis and declines in neuromuscular function (strength, power, gait and balance) which increases the risk of fracture and falls (a risk factor for fracture) and impairs physical function. Men on ADT are 1.4 times more likely to fracture compared with their cancer-free peers and those who fracture have a poorer prognosis than those who do not. Self-report physical function is also lower among men on ADT. Exercise can prevent bone loss, neuromuscular declines and falls in several populations. However, the ability of exercise to prevent bone loss from ADT has not been tested, while data on exercise and neuromuscular function (strength only) in this population are limited to one published trial. The long-term goal of our research is to improve musculoskeletal health and function in cancer survivors. Critical first steps to meet this goal are to determine whether our previously tested program of impact and resistance exercise, shown to improve bone health and neuromuscular function in women, can prevent bone loss and neuromuscular declines in prostate cancer survivors on ADT. Based on our previous research, we have developed the Prevent Osteoporosis With Impact + Resistance (POWIR) program to be adapted to clinical populations at risk for bone loss and declines in neuromuscular function. Potentially, POWIR could mitigate bone and muscle losses from ADT, and thereby lower fracture risk and improve quality of life.

Eligibility Criteria:
Inclusion Criteria:

* histologically confirmed prostate cancer
* presently receiving or planning to begin androgen deprivation therapy for prostate cancer

Exclusion Criteria:

* Presence of bone metastases in the proximal femur and lumbar spine
* Clinically defined osteoporosis
* Current or previous use of medications known to affect bone metabolism
* Current regular participation (\>2x/wk for at least 30 min/session) in a planned session of moderate-vigorous impact or resistance training
* A medical condition, disorder, or medication that contraindicates participation in moderate intensity impact or resistance exercise
The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria

The main purpose of the study is to compare the effects of three different types of RAAS blockade on 24 hours proteinuria in patients with non-diabetic chronic kidney disease.

Pharmacological blockade of the renin-angiotensin-aldosterone system (RAAS) is the main target of therapy to reduces both proteinuria and the rate of decline of the glomerular filtration rate in non-diabetic chronic renal diseases. Despite recent progress, however, there is still no optimal therapy that can stop the progression of these nephropathies. Therefore, it is necessary to optimize such treatment for further improving renal outcome.

The aim of the present study was to compare the effects of three different types of RAAS blockade: (1) mineralocorticoid receptor blocker (MRB) + angiotensin receptor antagonist (ARA); (2) direct renin inhibitor (DRI) + ARA and (3) double maximal dose of ARA on 24 hours proteinuria in patients with non-diabetic chronic kidney disease

Eligibility Criteria:
Inclusion Criteria:

* age 18-65 years
* chronic non-diabetic proteinuric nephropathy
* chronic kidney disease stage 1-3
* stable proteinuria above 500 mg/24 hours
* blood pressure above 125/75 mmHg and below 150/95 mmHg
* no steroids or other immunosuppressive treatment for a minimum of six months before the study

Exclusion Criteria:

* unstable coronary heart disease
* decompensated congestive heart failure in the previous 6 months
* episode of malignant hypertension or stroke in the history
* diabetes
* creatinine clearance below 30 ml/min
* pregnancy
Association of Egg and Dietary Cholesterol Consumption With Mortality and Diseases

To assess the associations between egg and dietary cholesterol consumption with mortality and metabolic syndrome (MetS).

Substitution models, sensitivity analyses, subgroup analyses and multiple linear regression analyses will be conducted to specifically estimate the hazard ratios and 95% confidence intervals of mortality and MetS associated with egg and cholesterol consumption.

Eligibility Criteria:
Inclusion Criteria:

* participants aged ≥20 y

Exclusion Criteria:

* missing creatinine, age, cannot be linked to socio-demographic data; aged less than 20; without complete dietary data .
Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer

To evaluate the efficacy of continuation targeted therapy compared with trastuzumab combined with Pyrotinib and capecitabine in postoperative adjuvant therapy of HER-2 positive early breast cancer patients with residual tumor (primary breast tumor/axillary lymph nodes) who did not achieve pCR after neoadjuvant therapy


Eligibility Criteria:
Inclusion Criteria:

* Female patients aged ≥ 18 years and ≤ 75 years old with primary breast cancer
* ECOG score 0 \~ 1
* Breast cancer meets the following criteria: 1）Histologically or pathologically confirmed invasive breast cancer, primary tumor stage determined by standard evaluation methods：cT1-4/N0-3/M0. 2）Pathologically confirmed HER2-expressing positive breast cancer, defined as \> 10% immunoreactive cells with immunohistochemical (IHC) score of 3 + or in situ hybridization (ISH) results of HER2 gene amplification. 3)Known hormone receptor status (ER and PgR). 4)Neoadjuvant therapy (including: at least 9 weeks of trastuzumab treatment and at least 9 weeks of taxane chemotherapy)
* Primary breast cancer lesion or lymph node invasive cancer confirmed by pathology after neoadjuvant therapy (residual invasive breast cancer lesion \> 2 cm or axillary lymph node positive with macrometastasis assessed by central laboratory)
* No more than 12 weeks between end of surgery (without post-operative radiotherapy) and randomisation or 6 weeks between end of post-operative radiotherapy and randomisation
* Required laboratory values including following parameters:

ANC: ≥ 1.5 x 109/L Platelet count: ≥ 90 x 109/L Hemoglobin: ≥ 9.0 g/dL Total bilirubin: ≤ 1.5 x upper limit of normal, ULN ALT and AST: ≤ 1.5 x ULN BUN and creatine clearance rate: ≥ 50 mL/min LVEF: ≥ 55% QTcF: \< 470 ms

Exclusion Criteria:

* 1) Stage IV (metastatic) breast cancer;
* 2) inflammatory breast cancer;
* 3) Previous anti-tumor therapy or radiotherapy for any malignancy, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;
* 4) Receiving anti-tumor therapy in other clinical trials, including bisphosphonate therapy or immunotherapy (except radiotherapy and endocrine therapy during treatment);
* 5) Receiving any anti-tumor therapy within 28 days before enrollment;
* 6) Peripheral neuropathy ≥ Grade 2 as specified by NCI CTCAE;
* 7) Receiving pyrrolidone or other anti-HER2 tyrosine kinase inhibitors;
* 8) Receiving anthracycline therapy with cumulative doses as follows: adriamycin \> 240 mg/m2, epirubicin \> 480 mg/m2;
* 9) Receiving major surgery unrelated to breast cancer before randomization, or the patient has not fully recovered from surgery
Effectiveness of Acupuncture in Post-Mastectomy Patients With Tissue Expanders

The primary purpose of this study is to evaluate changes in shoulder tightness, chest tightness, and general pain related to post-mastectomy reconstructive surgery with tissue expansion in women who are randomized to receive acupuncture treatment immediately after surgery (twice a week for 6 weeks) compared to those who are randomized to no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.


Eligibility Criteria:
Inclusion Criteria:

* Women who are newly diagnosed with breast cancer, enrolled in the The Breast Cancer Database of NYU Cancer Center (BCD) and who are having breast cancer surgery involving a mastectomy procedure with insertion of a tissue expander for reconstructive purposes
* Women who are newly diagnosed with breast cancer
* Women who are enrolled in the Breast Cancer Database (BCD)
* Women who are having breast cancer surgery involving a mastectomy procedure with insertion of a tissue expander for reconstructive purposes

Exclusion Criteria:

* Women who had neoadjuvant chemotherapy and/or radiation therapy, women who are currently on anticoagulant therapy, women who are having breast reconstruction with Alloderm, women who have chronic pre-operative pain, and/or women who have had a history of previous implants or prior augmentations
* Women who had neoadjuvant chemotherapy and/or radiation therapy
* Women who are currently on anticoagulant therapy
* Women who are having breast reconstruction with Alloderm
* Women who have chronic pre-operative pain
* Women who have had a history of previous implants or prior augmentations
* Women who are currently on anticoagulant therapy
* Women who are having breast reconstruction with Alloderm
* Women who have chronic pre-operative pain
* Women who have had a history of previous implants or prior augmentations
Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®. The purpose of this study is to increase the understanding of the role of L-methylfolate among patients who are candidates for Deplin®, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for depression.

Surveys used to conduct this study will be administered via telephone or online by InfoMedics, Inc., a company with a system for developing such patient-physician feedback programs. Participating physicians will ask their patients to participate in the program after Deplin® has been prescribed and provide them with a brochure containing an introduction to the program and instructions on how to enroll. Patients self-enroll, take a brief survey before starting their Deplin® prescription, and then a follow-up survey after 90 days of treatment with Deplin®. As patients complete surveys within the study, their physician will receive individualized feedback reports outlining their patient's treatment experience and progress. Patients will also receive a copy of their own reports, to help encourage them to continue taking Deplin® as directed. Patients will also receive educational materials about managing their depression.

Eligibility Criteria:
Inclusion Criteria:

* New Deplin® Start
* Only for patients with depression who have been prescribed brand name Deplin® to help metabolic management of depression.
* Clinically depressed patients who have been prescribed Deplin® in combination with an antidepressant.
* At the start of antidepressant therapy
* As augmentation to antidepressant therapy

Exclusion Criteria:

* Patients who do not meet DSM IV criteria for major depression
* If participant indicates that he or she did not get a prescription for Deplin®, he/she will not be able to complete the survey(s).
* For follow-up surveys, if the participant indicates that he/she has not been taking Deplin®, he/she will not be able to complete the survey(s).
CAREGIVER2, Caregiver's Health Assessment : Clinical and Biological Markers

Providing care for a disabled elderly may represent a risk for the health of the caregiver. The objective of the study is to assess the impact of caregiving in terms of clinical and biological markers in relation to disability and cognitive impairment.

The investigators hypothesize that an accumulation of stressful events related to care giving may induce a stress response to the caregiver. This stress response can be measured by biological markers (inflammation, transcription and immunity) and also by clinical markers (frailty, physical performance, nutrition). This stress response can be influenced by the subjective burden of the caregiver and by the severity of the disease of the care receiver (Activity of daily life capabilities, cognitive function, behavioral disturbance).

Eligibility Criteria:
Inclusion Criteria:

* living with the care-receiver ( or with a healthy elderly for the controls)
* care-receiver dependent for at least one Activity of the daily living ( Katz index) or having cognitive disorder ( \>2 Global Deterioration Scale)

Exclusion Criteria:

* institutionalised elderly
* inability to understand and speak french
* Acute disease within the past month
* Anti-inflammatory or immuno-suppressive treatment
* End-of-life care
Assessment of the Perceptions and Opinions of Staff Working of Prisons and Detention Centers on the Use of Psychoactive Substances in Prisons and Harm Reduction (PERRCEP)

Evaluation, through an anonymous questionnaire, of the perceptions and opinions of staff working in prisons and detention centers in Brittany regarding the consumption of illicit substances and harm reduction measures in prison environment. The secondary objective of the study will be to assess training needs and explore factors associated with better adherence to the implementation of harm reduction measures.

A first contact will be made by email with the heads of institutions, directors of Penitentiary Rentegration Services), and coordinating doctors of healthcare units to inform them about the study's objectives and procedures, and to request their institution's and service's participation.

If they agree to participate, volunteer key contacts will be identified in each institution to relay the information to the staff working in the institution and ensure the distribution of the questionnaire.

The study's responsible doctor will meet with one of the resident investigators for a preliminary informational meeting with the institution's director, the SPIP director, and the identified key staff members. The questionnaires will be handed to the key contacts at that time.

A "non-opposition" letter will be individually distributed with each anonymous questionnaire to provide further details about the study for which their participation is requested.

After answering, participants will be able to place the questionnaire in the provided envelope, and then into a sealed ballot box.

After the answering period, the investigator will go back to prisons and detention centers to collect the ballot boxes.

The data from each paper questionnaire will be transcribed by the residents onto an online platform using the Lime Survey® software.

The statistician of UBO (university of Brest) will have access to the data on Lime Survey® in order to perform the statistical analyses as described below.

The statistician will make a descriptive analysis of the results and the an analytical study will research factors associated with improved adherence to harm reduction mesures : profession exercised; seniority; harm reduction training; age

Eligibility Criteria:
Inclusion Criteria:

* working person of remand center of Brest, Vannes, Rennes, Saint-Malo, Lorient and Saint-Brieuc, who has answered the questionnaire
* working person of detention center of Lorient and Rennes, who answered the questionnaire

Exclusion Criteria:

* person opposing participation in the study
* person under legal protection measure
Enhancing Prospective Thinking in Early Recovery (NERF)

The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:

Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? Will high-intensity EFT cues effect greater treatment-seeking interest? Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity) Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS? Will the novel behavioral SS decision-making task activate the nucleus accumbens? Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above.


Eligibility Criteria:
Inclusion Criteria:

* Abstinence between 30 days ≤ 1 year
* Verbal endorsement of commitment to recovery
* English comprehension

Exclusion Criteria:

* Unstable medical disorders
* Outside the age range of 18-60
* Habitual substance or alcohol use
* Smell/taste disorders
* Unstable psychiatric conditions
The Impact of Workplace Food and Beverage Choices on Health and Wellness

The study is designed to determine if instituting a Healthy Beverage Initiative (HBI) at hospitals influences health and wellness of employees over a 12 month period.

To examine whether HBI is associated with decreased adiposity over a 12-month time period, in comparison to individuals identically assessed but not exposed to a HBI. Specifically, do those exposed to the HBI decrease in measures of adiposity, BMI, and sugar sweetened beverage (SSB) intake? Do they decrease more in those measures as compared to those not exposed to the HBI?

Eligibility Criteria:
Inclusion Criteria:

* The participant speaks and reads English.
* The participant consumes three or more sugar-sweetened beverages a week.
* The participant expects to be able to participate for all 3 visits (baseline, 6 months, and 12 months).

Exclusion Criteria:

The participant is planning an extended leave of absence and/or family medical leave of absence over the next 12 months.
A Study of T-20 in HIV-Positive Adults

The purpose of this study is to see if it is safe and effective to give T-20 to HIV-positive adults. T-20 is an anti-HIV drug.

Patients are randomly placed into 1 of 6 groups: 4 dose levels of T-20 are given by subcutaneous infusion and 2 by subcutaneous injection. The entire study lasts 7 weeks; including a 2-week screening period, followed by 28 days of treatment and 1 week of follow-up.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Any antiretroviral agent, provided the regimen has not changed within 6 weeks of the screening visit.
* Antibiotics for bacterial infections.
* Prophylactic medications for P. carinii pneumonia and for M. avium, including azithromycin.
* Medications for symptomatic treatment such as antipyretics, analgesics, and antiemetics.

Patients must have:

HIV-1 seropositive status.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Concurrent neoplasm (except for basal cell carcinoma of the skin, in situ carcinoma of the cervix, and non-disseminated stable Kaposi's sarcoma).

Concurrent Medication:

Excluded:

* Patients must not be taking any concurrent antiretroviral therapy (for at least 2 weeks prior to baseline) or the patient is to be on a stable antiretroviral regimen which has not changed for at least 6 weeks prior to baseline.
* Treatment with any of the following:
* immunomodulators, biological response modifiers, chemotherapy that cannot be discontinued for the duration of the study, astemizole, terfenadine, cisapride, triazolam, midazolam, rifampin, clarithromycin, or an investigational drug within 30 days prior to the initial visit.

Patients with the following prior conditions are excluded:

* Evidence of active opportunistic infections, or unexplained temperature greater than or equal to 38.5 Celsius for 7 consecutive days within 30 days prior to screening visit.
* Chronic diarrhea (defined as greater than 3 liquid stools per day which persists for 15 days) within 30 days prior to screening visit.
* Diagnosis of hemophilia or other clotting disorders.

Prior Medication:

Excluded:

- Prior treatment with an HIV vaccine.

Prior Treatment:

Excluded:

Major organ allograft.

Risk Behavior:

Excluded:

Evidence of substance abuse or addiction that, in the opinion of the investigator, may interfere with the patient's ability to comply with the dosing schedule and protocol evaluations.